HCC

Laura Dawson, MD, provides insight into the diagnosis and treatment of hepatocellular carcinoma.

A novel, evidence-based model for staging liver function in the setting of hepatocellular carcinoma may offer improved guidance in the selection of appropriate, patient-specific therapeutic strategies.

A recent phase III clinical trial has offered hope for the prophylactic management of hand-foot skin reaction in patients with hepatocellular carcinoma treated with sorafenib.

The small molecule multikinase inhibitor sorafenib remains the only molecularly targeted therapy approved by the FDA for the treatment of hepatocellular carcinoma, with ongoing clinical trials diligently testing the potential for novel targeted agents or combination therapies to further improve patient outcomes in this setting.

Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.

Laura Dawson, MD, FRCPC, professor, Department of Radiation Oncology, University of Toronto, discusses screening and prevention of hepatocellular carcinoma (HCC).

Growth in healthcare spending in the United States continues to outpace growth in European countries that enjoy a similar standard of living.

Representatives Diana DeGette (D, Colorado) and Fred Upton (R, Michigan) recently released a "discussion draft" of the 21st Century Cures Act.

Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.

An analysis of patients with advanced hepatocellular carcinom and elevated α-fetoprotein who received second-line ramucirumab showed a significant improvement in overall survival.

Two polymorphisms of a vasodilatory enzyme had significant associations with improved survival in liver cancer treated with an inhibitor of vascular endothelial growth factor receptor (VEGFR).

Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.

The anti-CD19 chimeric antigen receptor (CAR)-modified T-cell therapy CTL019 demonstrated a 92% complete response (CR) rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

The programmed death receptor-1 (PD-1) ligand, PD-L1, has become a viable target for immunotherapy in cancer, with multiple antibodies now in development.

As its CAR T cell and high-affinity TCR products continue to advance in clinical trials, Juno Therapeutics, Inc, filed a registration statement for an initial public offering (IPO) of its common stock on November 17.

Recent news stories profiling a cancer patient whose last hope rests on treatment by injections of the virus that causes AIDS may have created some misconceptions regarding a new cancer immunotherapy.

Hepatocellular carcinoma remains one of the most common tumors worldwide, and frequently carries a poor prognosis, with most patients being diagnosed at late stages of disease.

As with most cancers, early diagnosis and treatment of hepatocellular carcinoma (HCC) may result in more effective treatment and improved outcomes. Unfortunately, most patients with HCC are diagnosed at a late stage, when therapeutic options are limited and prognosis is poor.

Hepatocellular cancer (HCC) is a rapidly fatal malignancy that is often diagnosed at an advanced stage when it is not curable. Despite a rise in incidence, this cancer is not as common in the Western world as it is in Asia and Africa.

Melanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.

Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results of the phase III STORM trial in hepatocellular carcinoma.

The investigational CD19-targeted chimeric antigen receptor (CAR) therapy CTL019 has received a breakthrough therapy designation from the FDA as a potential treatment for pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

The liver is a common site of metastatic recurrence for many tumors. For a minority of patients, surgical resection may be an option; however, most patients will not qualify for surgery due to insufficient liver functional reserve or other contraindications.

Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.

Melanie B. Thomas, MD, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).